論文・技術情報追加のお知らせ

1. Disproportionality analysis of drug-associated tinnitus safety signals: a 43-year pharmacovigilance study.

薬剤性耳鳴りの安全シグナルをFAERSデータで包括解析。

対象DB：FAERS

2. Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.

高齢者におけるイピリムマブの市販後安全性をFAERSで評価。

対象DB：FAERS

3. Detection of clinically significant drug-drug interactions in serotonin syndrome: a multisource real-world data and pharmacovigilance study.

セロトニン症候群の薬物相互作用リスクを複数DBで検証。

対象DB：FAERS

4. A pharmacovigilance study of sirolimus-associated adverse events in organ transplantation.

臓器移植におけるシロリムスの副作用プロファイルを解析。

対象DB：FAERS

5. Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining.

SJS/TEN高リスク薬のデータマイニング研究に関する総説。

対象DB：FAERS

6. Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics.

薬剤性壊疽性膿皮症のリスク信号をFAERSデータで解析。

対象DB：FAERS

7. Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System.

HPVワクチン接種後の有害事象をVAERSデータで評価。

対象DB：FAERS,VAERS

8. Integrating Pharmacovigilance Data Mining and Mendelian Randomization to Identify Risk Profiles and Causal Targets of Opioid-Induced Delirium.

メンデルランダム化等を用いたオピオイドの副作用リスク解析。

対象DB：FAERS

9. Ocular Adverse Events Associated With Antidepressants: A Large-Scale Data Analysis From the FAERS Database.

抗うつ薬に関連する眼科的副作用をFAERSで包包括解析。

対象DB：FAERS

10. Pharmacovigilance Evaluation of Somatrogon-Associated Adverse Events in Real-World Databases.

新しい成長ホルモン製剤ソマトロゴンの安全性をDB解析。

対象DB：FAERS

11. Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database.

インフリキシマブの皮下注対静脈注の安全性をFAERSで比較。

対象DB：FAERS

12. Identification of Drug Associated Factors for Gingival Disorders: A Real-World Pharmacovigilance Study.

薬剤性歯肉障害のシグナルと関連因子をリアルワールド解析。

対象DB：FAERS

13. Analysis signals of disproportionate reporting associated with donanemab: A retrospective pharmacovigilance study using the FAERS database.

アルツハイマー病治療薬ドナネマブの市販後不均衡解析。

対象DB：FAERS

14. Adverse events of Alzheimer's disease patients treated with memantine-based therapies: A disproportionality analysis of the FAERS database based on the MY FAERS platform.

メマンチン併用療法の副作用プロファイルをFAERSで解析。

対象DB：FAERS

15. A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases.

ICI関連白斑の薬物監視およびオミクスデータによる統合解析。

対象DB：FAERS

16. Comprehensive analysis of cefuroxime-associated adverse events: Insights from JADER database (2004-2024) and comparison with FAERS database.

セフルキシムの副作用をJADER等のデータに基づき系統解析。

対象DB：FAERS,JADER

17. Signal mining and analysis of adverse events in children using growth hormones: A retrospective real-world study based on FAERS.

小児における成長ホルモン療法の副作用を大規模データで解析。

対象DB：FAERS

18. Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.

非糖尿病肥満患者でのGLP-1薬によるケトアシドーシスリスク。

対象DB：FAERS

19. Analysis of ocular adverse events associated with SNRIs.

SNRI使用に伴う眼科的副作用の不均衡解析。

対象DB：FAERS

20. Comparative thromboembolic risk and polypharmacy-related drug-drug interaction signals among antidiabetic medications: a large-scale FAERS pharmacovigilance study.

糖尿病薬の血栓塞栓リスクと相互作用シグナルの比較。

対象DB：FAERS

21. Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease.

ドライアイ治療薬ペルフルロヘキシルオクタンの安全シグナル。

対象DB：FAERS

22. Real world pharmacovigilance study of FDA adverse event reporting system events for Spiriva Respimat.

スピリーバレスピマットの副作用プロファイルをリアルワールド解析。

対象DB：FAERS

23. Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database.

SGLT2阻害薬の精神神経副作用シグナルをFAERSで解析。

対象DB：FAERS

24. A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review.

ドセタキセル投与後に急性心筋梗塞を発症した乳がん症例報告。

対象DB：FAERS

25. irAE.AI: AI-powered exploration of real-world immune-related adverse events.

AIを用いた免疫関連副作用のリアルワールド探索ツールの開発。

対象DB：FAERS

26. A Comprehensive Disproportionality Analysis of Drug-Related Head Injury Reports Using the FAERS Database.

薬剤関連の頭部外傷報告に関する不均衡解析。

対象DB：FAERS

27. Systematic analysis of the adverse effects of used clinical antisense oligonucleotide drugs in DMD patients based on the FAERS database.

DMDへのアンチセンス核酸医薬の副作用をFAERSで解析。

対象DB：FAERS

28. Signals of pericardial and myocardial events associated with antiangiogenic drugs: a disproportionality analysis on FAERS((R)).

抗血管新生薬による心膜・心筋イベントのシグナル解析。

対象DB：FAERS

29. Descriptive Analysis of DRESS Reports from EudraVigilance and DRESS Cases from the RegiSCAR-project.

DRESS症候群報告の複数データソースを用いた記述的分析。

対象DB：EudraVigilance

30. Higher disease reactivation risk in women after fingolimod withdrawal.

フィンゴリモド中止後の多発性硬化症再活性化リスクの性差。

対象DB：EudraVigilance

31. A 'One Health' cross-sectional analysis of reports of potential antibiotic resistance cases in international pharmacovigilance databases.

副作用DBを用いた抗菌薬耐性報告のOne Healthアプローチ解析。

対象DB：EudraVigilance,VigiBase

32. Cannabis and Cannabinoid-Related Suspected Adverse Drug Reactions: Global Patterns and Cross-National Analysis Based on VigiBase((R)) Data.

大麻・カンナビノイド関連副作用の世界的な傾向の分析。

対象DB：VigiBase

33. Exploring staffing and hospital factors associated with WardPharm-1 filing in Japan: a nationwide observational study.

日本における病棟薬剤業務実施加算算定に関連する因子の調査。

対象DB：DPC

34. Prognostic outcomes of adjuvant chemotherapy in postoperative patients with cancer undergoing hemodialysis versus non-hemodialysis patients: a retrospective nationwide cohort study.

透析を受ける術後がん患者への術後補助化学療法の予後。

対象DB：DPC

35. Clopidogrel, an ADP-P2Y12 Receptor Antagonist, Is Associated With Lower Opioid Consumption and a Reduced Incidence of Delirium in Cancer Patients Receiving Chemotherapy: A Nationwide Retrospective Cohort Study in Japan.

クロピドグレルがオピオイド消費量と呼吸抑制に与える影響。

対象DB：DPC

36. Association between menstrual-related disorders and sexually transmitted infections: A nationwide cross-sectional study in Japan.

月経関連障害と性感染症の関連に関する全国横断調査。

対象DB：JMDC

37. Prefecture-level factors associated with home-visit dental care utilization in Japan: focus on dentist workforce characteristics.

日本における訪問歯科診療の利用に関連する地域因子の分析。

対象DB：NDB

38. A nationwide survey of medical resource usage for cancer treatment using Japanese health claims data from 2011 to 2022.

日本のレセプトデータを用いたがん治療の医療資源利用動向。

対象DB：NDB

39. Age- and modality-specific trends in bone mineral density testing among women in Japan.

日本の女性における骨密度検査の年齢・モダリティ別動向。

対象DB：NDB

40. Treatment and burden of patients with chronic myeloid leukemia in Japan: A retrospective claims database analysis.

日本の慢性骨髄性白血病患者における治療パターンと経済負担。

対象DB：MDV

41. Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs.

日本の末梢性T細胞リンパ腫におけるリアルワールドの治療実態。

対象DB：MDV

42. Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.

チルゼパチドの日本人肥満患者における10年心血管リスク予測。

対象DB：MDV

43. Association of asymptomatic PSA testing on prostate cancer mortality; a case control study in general practice.

一般診療における無症状者へのPSA検査と前立腺がん死亡率。

対象DB：CPRD

44. Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA.

臨床試験デザインのフィージビリティ評価におけるRWEの活用例。

対象DB：CPRD

45. A novel dynamic risk score to predict venous thromboembolism recurrences after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer.

3ヶ月抗凝固療法後のがん合併VTE再発予測スコアの開発。

対象DB：CPRD

46. A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer.

3ヶ月抗凝固療法後のがん合併VTE出血予測スコアの開発。

対象DB：CPRD

47. Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study.

認知症高齢者における抗精神病薬の急な中止と漸減の比較。

対象DB：CPRD

48. Repurposing cardiovascular disease prediction models for cancer.

心血管疾患予測モデルのがん患者への流用可能性の検証。

対象DB：CPRD

49. Incidence of skin and soft-tissue infections in England: 11-year retrospective study.

イングランドにおける皮膚・軟部組織感染症の11年間の発症率。

対象DB：CPRD

50. Sociodemographic disparities in primary care management of back pain in children and young people: a population-based cohort study.

英国の子供・若年者における腰痛管理の社会人口統計学的格差。

対象DB：CPRD

51. A Preliminary Study on the Efficacy and Safety of a Novel Digital Therapeutic Device: A Randomized Clinical Trial in South Korean Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.

韓国における新しいデジタル医療機器の有効性と安全性のRCT。

対象DB：KAERS

52. Hypersensitivity to Intravenous Lipid Emulsions and Food Allergies: a Systematic Review of Case Reports.

静脈内脂質乳剤への過敏症と食物アレルギーの症例レビュー。

対象DB：CVAR

53. Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan.

局所進行NSCLCへの化学放射線療法後のデュルバルマブの転帰。

対象DB：DeSC

54. Long-Term Outcomes After Ischemic Stroke Across Atrial Fibrillation Phenotypes Defined by Detection Timing and Prior Anticoagulation Status.

脳梗塞後の心房細動発見時期別および抗凝固薬別の長期予後。

対象DB：DeSC

55. Trends in anti-osteoporosis pharmacotherapy and pharmacological initiation for secondary fracture prevention in Japan, 2017-2023.

日本における骨粗鬆症薬治療動向と二次骨折予防開始率の変遷。

対象DB：DeSC